New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities

References

• Brunning R, Orazi A, Germing U, et al. Myelodysplastic syndromes. In: Swerdlow S, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissue. Vol. 4, Lyon: IARC Press; 2008. p. 88–103.
   Google Scholar
• Neukirchen J, Lauseker M, Blum S, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res. 2014;38(1):57–64.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MH. Disease progression in myelodysplastic syndromes: do mesenchymal cells pave the way? Cell Stem Cell. 2014;14(6):695–697.
   PubMed Web of Science ®Google Scholar
• Medyouf H, Mossner M, Jann JC, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14(6):824–837.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–4395.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009;115(22):5202–5209.
   PubMed Web of Science ®Google Scholar
• Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011;35(12):1591–1596.
   PubMed Web of Science ®Google Scholar
• Van Den Berghe H, Cassiman JJ, David G, et al. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251(5474):437–438.
   PubMed Web of Science ®Google Scholar
• Hasserjian RP, Le Beau MM, List AF, et al., Myelodysplastic syndrome with isolated del(5q). In: Swerdlow SH CE, Harris NL et al. (editors.) WHO classification of tumours of hematopoietic and lymphoid tissues. (4th ed). Lyon, France: IARC Press; 2008. p. 102–103.
   Google Scholar
• Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011;4(1):61–69.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Fidler C, Strickson AJ, et al. Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. Genomics. 2000;66(1):26–34.
   PubMed Web of Science ®Google Scholar
• Lai F, Godley LA, Joslin J, et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001;71(2):235–245.
   PubMed Web of Science ®Google Scholar
• Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335–339.
   PubMed Web of Science ®Google Scholar
• Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2010;16(1):59–66.
   PubMed Web of Science ®Google Scholar
• Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117(9):2567–2576.
   PubMed Web of Science ®Google Scholar
• Fink EC, Krönke J, Hurst SN, et al. Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with Del(5q). Ash. 2014.
   Google Scholar
• Schneider RK, Ademà V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26(4):509–520.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–1465.
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009;106(31):12974–12979.
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, McGraw K, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013;32(9):1110–1120.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567.
   PubMed Web of Science ®Google Scholar
• Song SJ, Ito K, Ala U, et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 2013;13(1):87–101.
   PubMed Web of Science ®Google Scholar
• Smith AE, Kulasekararaj AG, Jiang J, et al. CSNK1A1 mutations and isolated del (5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. Lancet Haematol. 2015;2(5):e212–e221.
   PubMed Web of Science ®Google Scholar
• Bello E, Pellagatti A, Shaw J, et al. CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). Br J Haematol. 2015. DOI:10.1111/bjh.13563.
   PubMed Web of Science ®Google Scholar
• Heuser M, Meggendorfer M, Cruz MM, et al. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia. 2015. DOI:10.1038/leu.2015.49.
   Web of Science ®Google Scholar
• Toma A. A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO. J Clin Oncol. 2013;31(Suppl 15):Abstr 7002.
   Google Scholar
• Sardnal V, Rouquette A, Kaltenbach S, et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia. 2013;27(7):1610–1613.
   PubMed Web of Science ®Google Scholar
• Caceres G, McGraw K, Yip BH, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013;110(40):16127–16132.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev. 2013;27(5):243–259.
   PubMed Web of Science ®Google Scholar
• List AF. New therapeutics for myelodysplastic syndromes. Leuk Res. 2012;36(12):1470–1474.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. Leukemia. 2014;28(3):497–506.
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301(5895):89–92.
   PubMed Web of Science ®Google Scholar
• Hattori N, Ushijima T. Compendium of aberrant DNA methylation and histone modifications in cancer. Biochem Biophys Res Commun. 2014;455(1–2):3–9.
   PubMed Web of Science ®Google Scholar
• Del Rey M, O’Hagan K, Dellett M, et al. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia. 2013;27(3):610–618.
   PubMed Web of Science ®Google Scholar
• Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91(8):2985–2990.
   PubMed Web of Science ®Google Scholar
• Bies J, Sramko M, Fares J, et al. Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood. 2010;116(6):979–987.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448–3458.
   PubMed Web of Science ®Google Scholar
• Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120(10):2076–2086.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315–1325.
   PubMed Web of Science ®Google Scholar
• Grønbæk K, Müller-Tidow C, Perini G, et al. A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica. 2012;97(9):1380–1388.
   PubMed Web of Science ®Google Scholar
• Han H, Cortez CC, Yang X, et al. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet. 2011;20(22):4299–4310.
   PubMed Web of Science ®Google Scholar
• Jeong M, Goodell MA. New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells. Exp Hematol. 2014;42(8):609–617.
   PubMed Web of Science ®Google Scholar
• Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014;99(4):613–619.
   PubMed Web of Science ®Google Scholar
• Inoue D, Kitaura J, Togami K, et al. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. J Clin Invest. 2013;123(11):4627–4640.
   PubMed Web of Science ®Google Scholar
• Miller CA, Wilson RK, Ley TJ. Genomic landscapes and clonality of de novo AML. N Engl J Med. 2013;369(15):1473.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144–147.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094–1096.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Shao J, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27(6):1275–1282.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153–1158.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376–3382.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433.
   PubMed Web of Science ®Google Scholar
• Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25(4):442–454.
   PubMed Web of Science ®Google Scholar
• Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. DNMT3A mutations in acute myeloid leukemia. Blood. 2010;119(24):5824–5831.
   Web of Science ®Google Scholar
• Shivarov V, Gueorguieva R, Stoimenov A, et al. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res. 2013;37(11):1445–1450.
   PubMed Web of Science ®Google Scholar
• Gale RE, Lamb K, Allen C, et al. Simpson’s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072–2083.
   PubMed Web of Science ®Google Scholar
• Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839–943.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428–2436.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289–2301.
   PubMed Web of Science ®Google Scholar
• Yamazaki J, Taby R, Vasanthakumar A, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012;7(2):201–207.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513–1521.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021–4034.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang G, Yi Y, et al. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk Lymphoma. 2013;54(11):2466–2473.
   PubMed Web of Science ®Google Scholar
• Jin J, Hu C, Yu M, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS One. 2014;9(6):e100206.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–1996.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49(4):690–695.
   PubMed Web of Science ®Google Scholar
• Harel S, Cherait A, Berthon C, et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res. 2015;39(5):501–504.
   PubMed Web of Science ®Google Scholar
• Braun T, Cherait A, Berthon C, et al. Treatment with decitabine (DAC) after azacitidine (AZA) failure in high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML). Blood. 2013;122:21.
   Google Scholar
• Komrokji RS, Apuri S, Al Ali N, et al. Evidence for selective benefit of sequential treatment with azanucleosides in patients with myelodysplastic syndromes (MDS). J Clin Oncol. 2013; abstr 7113:134.
   Google Scholar
• Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327.
   PubMed Web of Science ®Google Scholar
• Duong VH, Bhatnagar B, Zandberg DP, et al. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leuk Lymphoma. 2015;56(6):1718–1722.
   PubMed Web of Science ®Google Scholar
• Wu P, Geng S, Weng J, et al. The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome. Leuk Res. 2015;39(2):216–220.
   PubMed Web of Science ®Google Scholar
• Valencia A, Masala E, Rossi A, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014;28(3):621–628.
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–1288.
   PubMed Web of Science ®Google Scholar
• Issa JP, Roboz G, Rizzieri D, et al. Abstract LB-214: interim results from a randomized phase 1–2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML. Cancer Res. 2012;72.
   Google Scholar
• Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-Aza-2ʹ-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010;9(5):1443–1450.
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2ʹ-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007;67(13):6400–6408.
   PubMed Web of Science ®Google Scholar
• Issa JJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;S1470–2045.
   Google Scholar
• Stein EM, Altman JK, Collins R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase 1 study in patients with IDH2 mutation positive advanced hematologic malignancies [abstract]. Blood. 2014;124(21):Abstract 115.
   Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605–613.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52–57.
   PubMed Web of Science ®Google Scholar
• Lund K, Cole JJ, VanderKraats ND, et al. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol. 2014;15(8):406.
   PubMed Web of Science ®Google Scholar
• Meldi K, Qin T, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015;125(5):1857–1872.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705–2712.
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G. Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leuk Lymphoma. 2014;1–26.
   Google Scholar
• Tickenbrock L, Klein HU, Trento C, et al. Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk Res. 2011;35(5):620–625.
   PubMed Web of Science ®Google Scholar
• Chen TC, Hou HA, Chou WC, et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J. 2014;e177.
   Google Scholar
• Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788–800.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24:1062–1065.
   PubMed Web of Science ®Google Scholar
• Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29(18):2499–2506.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–2506.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180–193.
   PubMed Web of Science ®Google Scholar
• Scheuermann JC, De Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010;465(7295):243–247.
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722–726.
   PubMed Web of Science ®Google Scholar
• Bravo GM, Lee E, Merchan B, et al. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol. 2014;166(5):646–659.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181–185.
   PubMed Web of Science ®Google Scholar
• Béguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677–692.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103–107.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104(5):1266–1269.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium. ASH Annual Meeting Abstracts. 2008;Abstract 3656.
   Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32(12):1242–1248.
   PubMed Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015;121(4):556–561.
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11(12):2049–2054.
   PubMed Web of Science ®Google Scholar
• Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;11–12:891–900.
   Web of Science ®Google Scholar
• Stifter G, Heiss S, Gastl G, et al. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol. 2005;75(6):485–491.
   PubMed Web of Science ®Google Scholar
• Zang DY, Goodwin RG, Loken MR, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98(10):3058–3065.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 2002;100(10):3639–3645.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109(11):4816–4824.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Ingram W, Hayden J, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110(3):847–850.
   PubMed Web of Science ®Google Scholar
• Kotsianidis I, Bouchliou I, Nakou E, et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia. 2009;23(3):510–518.
   PubMed Web of Science ®Google Scholar
• Yazji S, Giles FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003;17(11):2101–2106.
   PubMed Web of Science ®Google Scholar
• Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006;91(5):667–670.
   PubMed Web of Science ®Google Scholar
• Li X, Shi J, Wang M, et al. Cyclosporine combined with levamisole for lower-risk myelodysplastic syndromes. Acta Haematol. 2015;134(3):138–145.
   PubMed Web of Science ®Google Scholar
• Scott BL, Ramakrishnan A, Fosdal M, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010;149(5):706–710.
   PubMed Web of Science ®Google Scholar
• Scott BL, Ramakrishnan A, Storer B, et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol. 2010;148(6):944–947.
   PubMed Web of Science ®Google Scholar
• Baron F, Suciu S, Amadori S, et al. Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica. 2012;97(4):529–533.
   PubMed Web of Science ®Google Scholar
• Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13(3):285–299.
   PubMed Web of Science ®Google Scholar
• Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013;123(11):4595–4611.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Germing U, Giagounidis A, et al. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study. Leuk Res. 2015;39(S1):S1–S166.
   PubMed Web of Science ®Google Scholar
• Komrokji R, Garcia-Manero G, Ades L, et al. A phase 2, dose-finding study of sotatercept (ACE-011) in patients with lower-risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML) and anemia requiring transfusion. Leuk Res. 2015;39:S5–S6.
   Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Bour-Jordan H, Esensten JH, Martinez-Llordella M, et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev. 2011;241(1):180–205.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–9553.
   PubMed Web of Science ®Google Scholar
• Ogata K, Kakumoto K, Matsuda A, et al. Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res. 2012;36(10):1229–1236.
   PubMed Web of Science ®Google Scholar
• Tamari R, Castro-Malaspina H. Transplant for MDS: challenges and emerging strategies. Best Pract Res Clin Haematol. 2015;28(1):43–54.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–2050.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Potter VT, Barber LD, et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2013;19(4).
   PubMed Web of Science ®Google Scholar
• Takami A, Yano S, Yokoyama H, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785–1790.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229–1235.
   PubMed Web of Science ®Google Scholar
• Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009;106(37):15825–15830.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–69.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–1395.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247.
   PubMed Web of Science ®Google Scholar
• Bacher U1KA, Haferlach T2. Mutational profiling in patients with MDS: ready for every-day use in the clinic? Best Pract Res Clin Haematol. 2015;28(1):32–42.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Podoltsev N, Gore SD, et al. The evolving field of prognostication and risk stratification in MDS: recent developments and future directions. Blood Rev. 2015;pii:S0268-960X(15)00046-6. doi:10.1016/j.blre.2015.06.004.
   Web of Science ®Google Scholar
• Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363(11):1025–1037.
   PubMed Web of Science ®Google Scholar
• Elias HK, Schinke C, Bhattacharyya S, et al. Stem cell origin of myelodysplastic syndromes. Oncogene. 2014;33(44):5139–5150.
   PubMed Web of Science ®Google Scholar
• Woll PS, Kjällquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794–808.
   PubMed Web of Science ®Google Scholar
• Erba HP, Othus M, Walter RB, et al. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res. 2014;38(3):329–333.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Popplewell L, Kirschbaum MH, et al. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients with relapsed/refractory myeloid malignancies: evidence of activity in patients with RAS mutation. J Clin Oncol. 2011;29(15):abstr 6506.
   Google Scholar
• Follo MY, Mongiorgi S, Bosi C, et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res. 2007;67(9):4287–4294.
   PubMed Web of Science ®Google Scholar
• Xu F, He Q, Li X, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014;4:7310.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al. Overall survival and subgroup analysis from a randomized phase III study of intravenous rigosertib versus best supportive care (BSC) in patients (pts) with higher-risk myelodysplastic syndrome (HR-MDS) after failure of hypomethylating agents (HMAs). 56th ASH Annual Meeting and Exposition. 2014;163( Session 637).
   Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803.
   PubMed Web of Science ®Google Scholar